New drug duo takes on tough bladder cancer
NCT ID NCT04004442
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether combining two drugs—avelumab (an immunotherapy) and AVB-S6-500 (a targeted therapy)—is safe and can help people with advanced bladder cancer that has worsened after chemotherapy. Nineteen adults with inoperable or metastatic urothelial carcinoma will receive both drugs intravenously every two weeks. The main goal is to check for side effects, while also tracking how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- avelumab and AVB-S6-500
- What this could lead to
- If this combination proves safe and effective, it could offer a new treatment option for advanced bladder cancer that has stopped responding to chemotherapy.
- What could go wrong
- This is a very early, small Phase 1 trial with only 19 participants, so results may not apply broadly. The combination may cause significant side effects or fail to control the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can a Two-Drug attack shrink Hard-to-Treat bladder tumors?
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
- New antibody aims to unlock immune attack on Hard-to-Treat cancers